Destetrapeptide insulin (DTI, human insulin with B27-30 removed) was obtain
ed from a monomeric precursor (MIP) expressed in Saccharomyces cerevisiae t
hrough tryptic transpeptidation in the presence of synthetic tetrapeptide G
ly-Phe-Phe-Tyr. The in vivo biological activity of DTI, determined by mouse
convulsion assay, is 22 IU/mg, Its binding activity with insulin receptor
on human placental membrane is 80% and its in vitro biological activity, de
termined by free fat cell assay, is 77%. Compared with native insulin, DTI
molecules do not associate in solution but exist in the monomeric form, thu
s leading to its rapid utilization in vivo.